ANGIOTENSIN II TREATMENT OF ENDOMETRIAL STROMAL CELLS MODULATES FIRST TRIMESTER TROPHOBLAST CELL FUNCTION

MACCHI R; ZAVATTIERI L; SALAVERRY L; PARRADO CECILIA; CASTRO MS; REY-ROLDÁN ESTELA; CANELLADA AM

Mar del Plata

Congreso; LXX ANNUAL MEETING OF SOCIEDAD ARGENTINA DE INMUNOLOGÍA (SAI) & 3RD FRENCH-ARGENTINE IMMUNOLOGY CONGRESS (FAIC); 2022

Sociedad Argentina de Inmunología

Prenatal exposure to Angiotensin Converting Enzyme inhibitors orAngiotensin II (Ang II) AT1 receptor blockers has been associatedwith adverse pregnancy outcomes. Given Ang-II treated T-HESCconditioned media increased trophoblast cell migration, we aim tofurther explore their effect on early pregnancy trophoblast functionand related cytokine secretion. T-HESC were pretreated or notwith either AT1R antagonist losartan (Los) (5μM) or NFAT inhibitorINCA-6 (10μM) for 30 min and/or Ang II (1.25-5x10-7M) for 48 h;culture medium was replaced and after 3 days conditioned media(CM) were obtained. HTR-8/Sv neo (H8) cell invasion was assessedthrough transwell invasion assay; tube formation was assessedthrough endothelial-like tube formation assay. H8 were pretreatedor not with either JNK inhibitor SP600125 (SP) (10μM) or mTORinhibitor Rapamycin (R) (50nM). TGFβ production was assessed byWestern Blot; IL-6 and VEGF production was assessed by ELISA.Differences were considered statistically significant with p